The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication

EBioMedicine

Volumn 8, Issue , 2016, Pages 217-229

  Walker Sperling, Victoria E ^a   Pohlmeyer, Christopher W ^a   Tarwater, Patrick M ^b   Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

CD8+ T cells; Elite controllers; Elite suppressors; Eradication; HIV 1; Latency reversal agents

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ABACAVIR; BRYOSTATIN 1; COBICISTAT PLUS DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; INTERLEUKIN 2; LAMIVUDINE; LATENCY REVERSAL AGENT; MISCELLANEOUS DRUGS AND AGENTS; PANOBINOSTAT; PROSTRATIN; RALTEGRAVIR; ROMIDEPSIN; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORINOSTAT; BIOLOGICAL MARKER; BRYOSTATIN; CYTOKINE; DEPSIPEPTIDE; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL DEATH; CELL ISOLATION; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SHOCK; VIRAL CLEARANCE; VIRUS REPLICATION; CD4+ T LYMPHOCYTE; DRUG EFFECTS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; BRYOSTATINS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DEPSIPEPTIDES; FEMALE; HIV INFECTIONS; HIV-1; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALE; RECEPTORS, ANTIGEN, T-CELL; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84964301410     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.04.019     Document Type: Article

References (45)

1. Akimova T., Ge G., Golovina T., Mikheeva T., Wang L., Riley J.L., Hancock W.W. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 2010, 136(3):348-363. 10.1016/j.clim.2010.04.018.
2. Akimova T., Beier U.H., Liu Y., Wang L., Hancock W.W. Histone/protein deacetylases and T-cell immune responses. Blood 2012, 119(11):2443-2451. 10.1182/blood-2011-10-292003.
3. Archin N.M., Margolis D.M. Emerging strategies to deplete the HIV reservoir. Curr. Opin. Infect. Dis. 2014, 27:29-35. 10.1097/QCO.0000000000000026.
4. Archin N.M., Liberty A.L., Kashuba A.D., Choudhary S.K., Kuruc J.D., Crooks A.M., Parker D.C., Anderson E.M., Kearney M.F., Strain M.C., Richman D.D., Hudgens M.G., Bosch R.J., Coffin J.M., Eron J.J., Hazuda D.J., Margolis D.M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487(7408):482-485.
5. Ariza M.E., Ramakrishnan R., Singh N.P., Chauhan A., Nagarkatti P.S., Nagarkatti M. Bryostatin-1-1, a naturally occurring antineoplastic agent, acts as a toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J. Biol. Chem. 2011, 286(1):24-34. 10.1074/jbc.M110.135921.
6. Bauer S., Hilger R.A., Mühlenberg T., Grabellus F., Nagarajah J., Hoiczyk M., Reichardt A., Ahrens M., Reichardt P., Grunewald S., Scheulen M.E., Pustowka A., Bock E., Schuler M., Pink D. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br. J. Cancer 2014, 110(5):1155-1162.
7. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., Lederman M.M., Benito J.M., Goepfert P.A., Connors M., Roederer M., Koup R.A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
8. Buckheit R.W., Salgado M., Silciano R.F., Blankson J.N. Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors. J. Virol. 2012, 86(24):13679-13688. 10.1128/JVI.02439-12.
9. Bullen C.K., Laird G.M., Durand C.M., Siliciano J.D., Siliciano R.F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 2014, 20(4):425-429. 10.1038/nm.3489.
10. Contreras X., Schweneker M., Chen C.S., McCune J.M., Deeks S.G., Martin J., Peterlin B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 2009, 284(11):6782-6789. 10.1074/jbc.M807898200.
11. DeChristopher B.A., Loy B.A., Marsden M.D., Schrier A.J., Zack J.A., Wender P.A. Designed, synthetically accessible bryostatin-1 analogues potently induce activation of latent HIV reservoirs in vitro. Nat. Chem. 2012, 4(9):705-710. 10.1038/nchem.1395.
12. Drexler H.G., Gignac S.M., Pettit G.R., Hoffbrand A.V. Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin-1 on human B cell activation and proliferation. Eur. J. Immunol. 1990, 20(1):119-127.
13. Darcis G., Kula A., Bouchat S., Fujinaga K., Corazza F., Ait-Ammar A., Delacourt N., Melard A., Kabeya K., Vanhulle C., Van Driessche B., JS Gatot, Cherrier T., LF Pianowski, Gama L., Schwartz C., Vila J., Burny A., Clumeck N., Moutschen M., De Wit S., BM Peterlin, Rouzioux C., Rohr O., Van Lint C. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1-1 + JQ1 and ingenol-B + JQ1 to potently reactivate viral gene expression. PLoS Pathog. 2015, 11(7). 10.1371/journal.ppat.1005063.
14. Gulakowski R.J., McMahon J.B., Buckheit R.W., Gustafson K.R., Boyd M.R. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antivir. Res. 1997, 33(2):87-97.
15. Hersperger A.R., Pereyra F., Nason M., Demers K., Sheth P., Shin L.Y., Kovacs C.M., Rodriguez B., Sieg S.F., Teixeira-Johnson L., Gudonis D., Goepfert P.A., Lederman M.M., Frank I., Makedonas G., Kaul R., Walker B.D., Betts M.R. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6. 10.1371/journal.ppat.1000917.
16. Hess A.D., Silanskis M.K., Esa A.H., Pettit G.R., May W.S. Activation of human T lymphocytes by bryostatin-1. J. Immunol. 1988, 141(10):3263-3269.
17. Hezareh M., Moukil M.A., Szanto I., Pondarzewski M., Mouche S., Cherix N., Brown S.J., Carpentier J.L., Foti M. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir. Chem. Chemother. 2004, 15(4):207-222.
18. Jiang G., Mendes E.A., Kaiser P., Wong D.P., Tang Y., Cai I., Fenton A., Melcher G.P., Hildreth J.E., Thompson G.R., Wong J.K., Dandekar S. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog. 2015, 11(7). 10.1371/journal.ppat.1005066.
19. Jones R.B., O'Connor R., Mueller S., Foley M., Szeto G.L., Karel D., Lichterfeld M., Kovacs C., Ostrowski M.A., Trocha A., Irvine D.J., Walker B.D. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. 2014, 10(8). 10.1371/journal.ppat.1004287.
20. Kelly-Sell M.J., Kim Y.H., Straus S., Benoit B., Harrison C., Sutherland K., Armstrong R., Weng W.K., Showe L.C., Wysocka M., Rook A.H. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am. J. Hematol. 2012, 87(4):354-360. 10.1002/ajh.23112.
21. Kulkosky J., Culnan D.M., Roman J., Dornadula G., Schnell M., Boyd M.R., Pomerantz R.J. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001, 98(10):3006-3015.
22. Laird G.M., Bullen C.K., Rosenbloom D.I., Martin A.R., Hill A.L., Durand C.M., Siliciano J.D., Siliciano R.F. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 2015, 125(5):1901-1912. 10.1172/JCI80142.
23. Li Z., Guo J., Wu Y., Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of tat-transactivation. Nucleic Acids Res. 2013, 41(1):277-287. 10.1093/nar/gks976.
24. Migueles S.A., Connors M. Success and failure of the cellular immune response against HIV-1. Nat. Immunol. 2015, 16(6):563-570. 10.1038/ni.3161.
25. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., Van Baarle D., Kostense S., Miedema F., McLaughlin M., Ehler L., Metcalf J., Liu S., Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 2002, 3:1061-1068.
26. Migueles S.A., Osborne C.M., Royce C., Compton A.A., Joshi R.P., Weeks K.A., Rood J.E., Berkley A.M., Sacha J.B., Cogliano-Shutta N.A., Lloyd M., Roby G., Kwan R., McLaughlin M., Stallings S., Rehm C., O'Shea M.A., Mican J., Packard B.Z., Komoriya A., Palmer S., Wiegand A.P., Maldarelli F., Coffin J.M., Mellors J.W., Hallahan C.W., Follman D.A., Connors M. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009-1021. 10.1016/j.immuni.2008.10.010.
27. O'Connell K.A., Bailey J.R., Blankson J.N. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol. Sci. 2009, 30(12):631-637. 10.1016/j.tips.2009.09.005.
28. Pohlmeyer C.W., Buckheit R.W., Siliciano R.F., Blankson J.N. CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants. Retrovirology 2013, 10:152. 10.1186/1742-4690-10-152.
29. Remoli A.L., Marsili G., Battistini A., Sgarbanti M. The development of immune-modulating compounds to disrupt HIV latency. Cytokine Growth Factor Rev. 2012, 23(4-5):159-172. 10.1016/j.cytogfr.2012.05.003.
30. Rubin E.H., Agrawal N.G., Friedman E.J., Scott P., Mazina K.E., Sun L., Du L., Ricker J.L., Frankel S.R., Gottesdiener K.M., Wagner J.A., Iwamoto M. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res. 2006, 12(23):7039-7045.
31. Sáez-Cirión A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barré-Sinoussi F., Delfraissy J.F., Sinet M., Pancino G., Venet A., Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6776-6781.
32. Salio M., Valitutti S., Lanzavecchia A. Agonist-induced T cell receptor down-regulation: molecular requirements and dissociation from T cell activation. Eur. J. Immunol. 1997, 27(7):1769-1773.
33. Scheid C., Young R., McDermott R., Fitzsimmons L., Scarffe J.H., Stern P.L. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunother. 1994, 38(2):119-126.
34. Shan L., Deng K., Shroff N.S., Durand C.M., Rabi S.A., Yang H.C., Zhang H., Margolick J.B., Blankson J.N., Siliciano R.F. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36(3):491-501. 10.1016/j.immuni.2012.01.014.
35. Siliciano J.D., Siliciano R.F. HIV-1 eradication strategies: design and assessment. Curr. Opin. HIV AIDS 2013, 8:318-325. 10.1097/COH.0b013e328361eaca.
36. Smith B.D., Jones R.J., Cho E., Kowalski J., Karp J.E., Gore S.D., Vala M., Meade B., Baker S.D., Zhao M., Piantadosi S., Zhang Z., Blumenthal G., Warlick E.D., Brodsky R.A., Murgo A., Rudek M.A., Matsui W.H. Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk. Res. 2011, 35(1):87-94. 10.1016/j.leukres.2010.06.001.
37. Søgaard O.S., Graversen M.E., Leth S., Olesen R., Brinkmann C.R., Nissen S.K., Kjaer A.S., Schleimann M.H., Denton P.W., Hey-Cunningham W.J., Koelsch K.K., Pantaleo G., Krogsgaard K., Sommerfelt M., Fromentin R., Chomont N., Rasmussen T.A., Østergaard L., Tolstrup M. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015, 11(9).
38. Spivak A.M., Bosque A., Balch A.H., Smyth D., Martins L., Planelles V. Ex vivo bioactivity and HIV-1 latency reversal by ingenol dibenzoate and panobinostat in resting CD4(+) T cells from aviremic patients. Antimicrob. Agents Chemother. 2015, 59(10):5984-5991. 10.1128/AAC.01077-15.
39. Sung J.A., Lam S., Garrido C., Archin N., Rooney C.M., Bollard C.M., Margolis D.M. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J. Infect. Dis. 2015, 212(2):258-263. 10.1093/infdis/jiv022.
40. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., Wells A.D., Hancock W.W. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 2007, 13(11):1299-1307.
41. Walker-Sperling V.E., Cohen V.J., Tarwater P.M., Blankson J.N. Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells. J. Virol. 2015, 89(18):9631-9638. 10.1128/JVI.01454-15.
42. Warrilow D., Gardner J., Darnell G.A., Suhrbier A., Harrich D. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res. Hum. Retrovir. 2006, 22(9):854-864.
43. Wei D.G., Chiang V., Fyne E., Balakrishnan M., Barnes T., Graupe M., Hesselgesser J., Irrinki A., Murry J.P., Stepan G., Stray K.M., Tsai A., Yu H., Spindler J., Kearney M., Spina C.A., McMahon D., Lalezari J., Sloan D., Mellors J., Geleziunas R., Cihlar T. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014, 10(4). 10.1371/journal.ppat.1004071.
44. Williams S.A., Chen L.F., Kwon H., Fenard D., Bisgrove D., Verdin E., Greene W.C. Prostratin antagonizes HIV latency by activating NF-kappaB. J. Biol. Chem. 2004, 279(40):42008-42017.
45. Xing S., Bullen C.K., Shroff N.S., Shan L., Yang H.C., Manucci J.L., Bhat S., Zhang H., Margolick J.B., Quinn T.C., Margolis D.M., Siliciano J.D., Siliciano R.F. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 2011, 85(12):6060-6064. 10.1128/JVI.02033-10.